Your search for tysabri returned 28 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for tysabri returned 28 results

Sort Results:

Relevant Recent

Natalizumab 300mg/15mL; soln for IV infusion after dilution; preservative-free.

news

The FDA is warning healthcare providers of reported hepatic injury associated with Tysabri (natalizumab, from Biogen Idec).

news

The FDA has approved the use of Tysabri (natalizumab, from Biogen Idec) for the treatment of moderate-to-severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies.